Last updated: April 25, 2026
Litigation Summary and Analysis: AbbVie Inc. v. Sun Pharmaceutical Industries Limited (1:23-cv-00684)
What is the case and where is it filed?
AbbVie Inc. v. Sun Pharmaceutical Industries Limited is pending in the U.S. District Court for the District of Delaware under case no. 1:23-cv-00684. The matter is litigation between AbbVie and Sun Pharmaceuticals concerning patent rights tied to AbbVie’s pharmaceutical products.
What claims are asserted?
No complete, case-ready claim set is available in the provided input. A litigation summary that identifies (i) specific asserted patents, (ii) the drug(s) at issue, (iii) the statutory framework invoked (e.g., Hatch-Waxman 35 U.S.C. § 271(e)(2)), and (iv) the specific counts asserted cannot be produced without the underlying docket filings or a referenced complaint/patent list.
What is the procedural posture?
The provided input does not include docket status (e.g., motion to dismiss, claim construction, preliminary injunction stage, trial scheduling, or settlement briefing). A complete procedural posture analysis cannot be produced from the supplied information alone.
What is the infringement or invalidity theory?
A patent infringement and invalidity analysis requires:
- Identified asserted patents (numbers and expiration/priority context)
- Sun’s accused product(s) and regulatory submission basis (e.g., ANDA/BLA/505(b)(2))
- Claim terms allegedly met or not met
- Sun’s defenses (invalidity grounds, non-infringement positions, statutory defenses)
None of these inputs are present in the provided content, so a complete and accurate theory analysis is not possible.
How do parties’ positions typically map in this posture?
Without the complaint or relevant motions, it is not possible to map the parties’ specific positions in this case to the usual Hatch-Waxman framework (non-infringement, invalidity under §§ 101/102/103/112, forfeiture/estoppel arguments, or carve-outs). Producing a generic mapping would not be faithful to the actual litigation record.
What are the business and R&D implications?
Business impact depends on what AbbVie is seeking and what Sun is launching, which in turn depends on:
- The product and strength(s) at issue
- Time to decision or market entry
- Likelihood of injunction or early adjudication
- Patent-by-patent validity and infringement likelihood
- Settlement or design-around trajectory
Those inputs are not included in the provided message. A defensible investment-grade analysis cannot be produced.
Evidence table (what’s missing vs. what would be required)
| Litigation element |
Needed for analysis |
Provided in prompt |
| Asserted patent numbers |
Yes |
No |
| Product(s) at issue and strengths |
Yes |
No |
| Filing basis (ANDA/BLA) |
Yes |
No |
| Relief sought (injunction/damages) |
Yes |
No |
| Procedural events |
Yes |
No |
| Claims and claim construction issues |
Yes |
No |
| Infringement allegations |
Yes |
No |
| Invalidity/defenses |
Yes |
No |
Key Takeaways
- Case identification is confirmed: AbbVie Inc. v. Sun Pharmaceutical Industries Limited, 1:23-cv-00684 in the District of Delaware.
- A complete litigation summary cannot be produced from the provided input because the asserted patents, accused product details, and procedural record are not included.
- Actionable analysis (patent-by-patent, motion posture, and business impact) requires the docket filings or a complaint excerpt listing the asserted patents and claims.
FAQs
-
What does “1:23-cv-00684” mean?
It is the case identifier in the U.S. District Court, where “1” denotes the district’s case numbering scheme and “23” denotes the filing year.
-
Is this a Hatch-Waxman case?
The prompt does not state the statutory framework or regulatory submission at issue, so the filing type is not ascertainable from the provided information.
-
Which patents are asserted?
The asserted patent list is not included in the provided input.
-
What stage is the case in (motions, discovery, trial)?
The prompt does not include docket status or event dates, so the procedural stage cannot be determined.
-
What is the likely impact on Sun’s product launch and AbbVie’s exclusivity?
Launch timing and exclusivity impact depend on the asserted patents, relief sought, and any injunction posture, which are not provided.
References
[1] U.S. District Court for the District of Delaware, case no. 1:23-cv-00684 (AbbVie Inc. v. Sun Pharmaceutical Industries Limited).
